Cargando…

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

BACKGROUND: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L1 therapy) in combination with bevacizumab is associated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vienot, Angélique, Jacquin, Marion, Rebucci-Peixoto, Magali, Pureur, Dimitri, Ghiringhelli, François, Assenat, Eric, Hammel, Pascal, Rosmorduc, Olivier, Stouvenot, Morgane, Allaire, Manon, Bouattour, Mohamed, Regnault, Hélène, Fratte, Serge, Raymond, Eric, Soularue, Emilie, Husson-Wetzel, Stéphanie, Di Martino, Vincent, Muller, Allison, Clairet, Anne-Laure, Fagnoni-Legat, Christine, Adotevi, Olivier, Meurisse, Aurélia, Vernerey, Dewi, Borg, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387199/ https://www.ncbi.nlm.nih.gov/pubmed/37516867 http://dx.doi.org/10.1186/s12885-023-11065-0

Ejemplares similares

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T(H)1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
por: Rebucci-Peixoto, Magali, et al.
Publicado: (2022)

Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
por: Spehner, Laurie, et al.
Publicado: (2020)

The prodigal son
por: Britten, Benjamin, 1913-1976
Publicado: (1990)

Cilia - the prodigal organelle
por: Beales, Phil, et al.
Publicado: (2012)

Les prodiges : piéce en deux parties /
por: Vauthier, Jean
Publicado: (1958)

The return of the prodigal Goldstone boson
por: Kapusta, Joseph I., et al.
Publicado: (1995)

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
por: Evrard, Camille, et al.
Publicado: (2022)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
por: Aparicio, Thomas, et al.
Publicado: (2020)

ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature
por: Damerval, Margaux, et al.
Publicado: (2021)

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
por: de Rauglaudre, Bernadette, et al.
Publicado: (2022)

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020)

Prodigal: prokaryotic gene recognition and translation initiation site identification
por: Hyatt, Doug, et al.
Publicado: (2010)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

The prodigal tongue: the love-hate relationship between British and American English
por: Murphy, Lynne
Publicado: (2018)

Growth rate evolution in improved environments under Prodigal Son dynamics
por: Collins, Sinéad
Publicado: (2016)

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
por: Orillard, Emeline, et al.
Publicado: (2022)

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2018)

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
por: Brouquet, Antoine, et al.
Publicado: (2020)

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2020)

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer
por: Eberst, Guillaume, et al.
Publicado: (2022)

Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene
por: Rosmorduc, Olivier, et al.
Publicado: (2007)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer
por: Laheurte, Caroline, et al.
Publicado: (2019)

ProDiGe: Prioritization Of Disease Genes with multitask machine learning from positive and unlabeled examples
por: Mordelet, Fantine, et al.
Publicado: (2011)

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study
por: Gaiffe, E., et al.
Publicado: (2019)

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer
por: Boustani, Jihane, et al.
Publicado: (2020)

Signes et prodiges: il y a plus d’une façon d’écouter une histoire
por: Tudiver, Sari Lubitsch
Publicado: (2022)

Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management
por: Sommariva, Antonio, et al.
Publicado: (2022)

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial
por: Lambert, Aurélien, et al.
Publicado: (2017)

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
por: Modesto, Anouchka, et al.
Publicado: (2023)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
por: Vienot, Angélique, et al.
Publicado: (2020)

Continuous architecture: sustainable architecture in an agile and cloud-centric world
por: Erder, Murat, et al.
Publicado: (2016)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Epigenetic Reprogramming of CD4(+) Helper T Cells as a Strategy to Improve Anticancer Immunotherapy
por: Renaude, Elodie, et al.
Publicado: (2021)

Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial
por: Egea, Julie, et al.
Publicado: (2022)

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?
por: Godet, Yann, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r6qt3vevocgv921bsd2904h95v